🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› NSCLC
Clinical trial register · United States · industry-sponsored

NSCLC Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 22 Florida 14 New York 13 Texas 10 Massachusetts 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Revolution Medicines, Inc.3 Pfizer2 Tubulis GmbH2 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)2 BioAtla, Inc.1
State
California22 Florida14 New York13 Texas10 Massachusetts10
All 32 states
Target enrolment
to
30 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
NCT07806773NSCLC, Non Small Cell Lung Cancer
Tubulis GmbH
Phase 2
80
California, New Jersey
2026-11
Recruiting
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
Nuvectis Pharma, Inc.
Phase 1
54
Virginia
2026-08-17
Recruiting
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer
Revolution Medicines, Inc.
Phase 3
430
Florida
2026-08-14
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-05-06
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Tubulis GmbH
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110NSCLC
Eikon Therapeutics
Phase 2
70
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2024-02-06
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Recruiting
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT05877430NSCLC, HNSCC, Melanoma, Metastatic Cancer
CJ Bioscience, Inc.
Phase 1/2
160
California, Pennsylvania
2023-09-11
Recruiting
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
NCT05753722Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
Incendia Therapeutics
Phase 1
270
Arizona, Connecticut, Massachusetts, Oregon, Pennsylvania, Tennessee, Texas, Virginia
2023-03-03
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa
2022-12-29
Recruiting
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT05283330Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
Orano Med Theranostics, SAS
Phase 1
48
Illinois, Iowa, Kentucky, Maryland, Nebraska, Pennsylvania
2022-12-22
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
Genentech, Inc.
Phase 1
165
California, Colorado, Florida, Georgia, Massachusetts, Missouri, New Jersey, Tennessee
2022-10-20
Active, closed
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
Monte Rosa Therapeutics, Inc
Phase 1/2
174
Arizona, California, Connecticut, Kansas, Massachusetts, Michigan, Missouri, New York
2022-10-12
Recruiting
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
NCT05443126NSCLC
Ellipses Pharma
Phase 1/2
265
California, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan, New York
2022-09-30
Recruiting
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321Advanced Solid Tumor, NSCLC
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
80
Indiana, Texas, Washington
2022-08-25
Active, closed
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
NCT05180799NSCLC, Melanoma
BioAtla, Inc.
Phase 1/2
320
California, Georgia, Indiana, New Jersey, New York, Ohio, Oregon, Utah
2022-08-03
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
California
2021-12-28
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Rows per page Showing 1–25 of 30
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/nsclc

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.